Sponsor Overview
Explore verified public information about Alnylam Pharmaceuticals's expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 3 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Official Statements
Score contribution: 100 — 7 supporting sources.
“Alnylam will consider providing a requesting physician with access to a specific Alnylam investigational therapy, for the treatment of an individual patient outside of a clinical trial (compassionate use request), or through an Alnylam early access program (EAP) when certain conditions are met.”
“If you are a patient living in a country where lumasiran is not commercially available and are interested in seeking access to lumasiran through the early access program, please speak with your physician. Alnylam can only respond to a physician requesting access to lumasiran on behalf of a patient in his/her care.”
“In these circumstances, Alnylam will consider providing a requesting physician with access to a specific Alnylam investigational drug, for the treatment of an individual patient outside of a clinical trial, when certain conditions are met.”
“Alnylam’s Compassionate Use Policy outlines the circumstances in which we will consider providing treatment for an individual patient outside a clinical trial. We evaluate all requests in a fair and equitable manner.”
“En estas circunstancias, Alnylam considerará la posibilidad de proporcionarle a un médico, que así lo solicite, el acceso a un fármaco en investigación específico de Alnylam para el tratamiento de un paciente individual fuera de un ensayo clínico cuando se cumplan determinadas condiciones.”
“Expanded access and compassionate use programs can fundamentally change lives for patients, caregivers, and advocates. We have the opportunity to impact these patients in a positive way by offering early access to our innovative medicines when no adequate treatments are available.””
Past EAPs on ClinicalTrials.gov
Score contribution: 40 — 4 supporting sources.
Conditions: TTR-mediated Amyloidosis, Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Familial Amyloid Polyneuropathies, Amyloid Neuropathies, Amyloidosis, Hereditary, Transthyretin-Related
Conditions: Primary Hyperoxaluria
Conditions: Transthyretin-mediated Amyloidosis With Cardiomyopathy, ATTR Amyloidosis With Cardiomyopathy
Conditions: Acute Hepatic Porphyria
Reagan-Udall Foundation Insights
Disease/Category-Specific EA Policies/Criteria http://www.alnylam.com/medical-professionals/expanded-access-program/
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.